Literature DB >> 25545882

Safety, sterility and stability of direct-from-vial multiple dosing intravitreal injection of bevacizumab.

Taraprasad Das1,2, Srinivas Volety3, Saad M Ahsan3, Abhay K Thakur3, Savitri Sharma1,2, Tapas R Padhi1, Soumyava Basu1, Ch Mohan Rao3.   

Abstract

BACKGROUND: This study aims to determine the stability, sterility and safety of bevacizumab multiple dosing from a single vial without prior aliquoting.
METHODS: In-vitro and human study. Six bevacizumab vials, used in multiple patients on a single day by direct withdrawal from the vial, and stored in 4°C up to a variable period, were tested for stability (high-performance liquid chromatography; [HPLC]), sterility (culture), conformational stability by circular dichroism and fluorescence spectroscopy and the rubber cork structural integrity (electron microscopy [EM]).
RESULTS: HPLC of all six samples of used bevacizumab and the control bevacizumab sample were similar; culture was negative; and the EM of rubber corks did not show an open communication. Spectroscopic studies indicated drug conformational stability. Further, there was no infection or inflammation in 221 consecutive patients (973 injections) when bevacizumab was stored at 4°C and used for one week.
CONCLUSION: Bevacizumab does not lose stability when stored at 4°C. It may be used for a week by direct withdrawal from the vial without fear of infection or inflammation if all standard precautions related to intravitreal injection are adhered to.
© 2014 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  age-related macular degeneration; diabetic retinopathy; ocular drug therapy

Mesh:

Substances:

Year:  2015        PMID: 25545882     DOI: 10.1111/ceo.12489

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  6 in total

1.  Survey of Intravitreal Injection Preferences for the Treatment of Age-Related Macular Degeneration and Macular Edema Among Members of the Turkish Ophthalmological Association.

Authors:  V Levent Karabaş; Ecem Önder Tokuç; Figen Şermet
Journal:  Turk J Ophthalmol       Date:  2022-06-29

2.  Intravitreal bevacizumab.

Authors:  Bakulesh M Khamar
Journal:  Indian J Ophthalmol       Date:  2018-01       Impact factor: 1.848

3.  Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.

Authors:  Vivek B Wani; Jamal Al-Kandari; Khalid Sabti; Faisal Aljassar; Hussain Qali; Niranjan Kumar; Anilkumar Uboweja; Khalid Al-Sabah; Fahad A Diab; Saleh Al-Rashidi
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar

4.  A study on the contamination of injection bevacizumab on storage of multidose vials.

Authors:  Ketan Saoji; Hemant Trehan; Raja Narayanan; Lalit Verma
Journal:  Indian J Ophthalmol       Date:  2018-02       Impact factor: 1.848

5.  Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding.

Authors:  Julia de Lima Farah; Ronaldo Sano; Ieda Maria Longo Maugéri; Daniela Teixeira; Mayari Eika Ishimura; Gabriela Martins; Lycia M J Mimica; Cely Barreto da Silva; Carsten H Meyer; João Rafael de Oliveira Dias; Gabriel Costa de Andrade; Michel Eid Farah
Journal:  Int J Retina Vitreous       Date:  2018-10-24

6.  All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection.

Authors:  Dheepak Sundar; Taraprasad Das; Jay Chhablani; Atul Kumar; Namrata Sharma
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.